Acesso livre
Acesso livre

Alergia e Imunologia

Superimunidade contra COVID: um dos maiores desafios da pandemia – “Pessoas que se recuperaram da COVID-19 apresentaram resposta imunológica mais forte após serem vacinadas do que pessoas não previamente infectadas. Cientistas tentam descobrir o motivo.”

27 Out, 2021 | 12:37h

COVID super-immunity: one of the pandemic’s great puzzles – Nature

Revisão | Envolvimento torácico e padrões de imagem em doenças relacionadas a IgG-4.

26 Out, 2021 | 11:14h

Thoracic involvement and imaging patterns in IgG4-related disease – European Respiratory Review

 

Comentário no Twitter

 

Revisão | A infecção por SARS-CoV-2 ou a vacinação levam a uma imunidade duradoura?

25 Out, 2021 | 13:09h

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? – The Lancet Respiratory Medicine

 

Comentário no Twitter

 

Perspectiva | A ciência imperfeita dos testes de anticorpos para imunidade contra SARS-CoV-2.

22 Out, 2021 | 12:28h

The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity – JAMA

FDA autoriza o uso de doses de reforço das vacinas da Moderna e da Johnson & Johnson, e afirma que misturar e combinar é OK.

21 Out, 2021 | 11:29h

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN

Ver também:

FDA OKs mixing COVID vaccines; backs Moderna, J&J boosters – Associated Press

FDA OKs Moderna, J&J boosters, along with ‘mix and match’ approach – NBC News

Estudo de coorte | A efetividade da vacinação heteróloga AstraZeneca (AZ)/mRNA foi mais significativa (68%) do que a vacinação homóloga AZ/AZ (50%) contra Covid-19 sintomática na Suécia.

20 Out, 2021 | 12:08h

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe

Comentário: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Deve-se misturar e combinar a dose de reforço da vacina?

20 Out, 2021 | 12:06h

Should You Mix and Match Your Booster Shot? – The Atlantic

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Estratégia da Global Initiative for Asthma (GINA) 2021 – Resumo executivo e racional para mudanças importantes.

20 Out, 2021 | 12:02h

Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes – European Respiratory Journal

Revisão sistemática | Agentes anti-interleucina-13 ou anti-interleucina-4 podem ser adequados para adultos com asma descontrolada moderada/grave que não responderam a outros tratamentos.

20 Out, 2021 | 12:01h

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma – Cochrane Library

Resumo: Anti-interleukin-13 or anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and adults with asthma – Cochrane Library

 

Comentário no Twitter (fio – clique para saber mais)

 

Vacinas da China contra a COVID foram cruciais – agora, a imunidade está diminuindo.

19 Out, 2021 | 12:49h

China’s COVID vaccines have been crucial — now immunity is waning – Nature

Conteúdos relacionados:

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.